Superior Performance, Reliable Results.

The Canexia Health Fusions 2.0 assay is a partner-agnostic method that assays 150 target exons (146 total fusion target gene exons, 3 housekeeping gene exons, 1 variant gene exon) in 18 unique fusion driver genes, 1 variant gene, and 2 housekeeping genes.

This expertly curated list is of targeted fusion driver genes that are reported to be involved in oncogenic fusions with an extensive set of partner genes. Most have therapeutic compounds available.

The assay is designed to be performed in tissue from formalin-fixed paraffin-embedded (FFPE) tissue blocks or cytology cell blocks.

ALK2, 10, 16-22
BRAF2, 6-12,15,19
EGFR1-3, 7-9,11, 13,16, 20-21, 24-25, 27, 8, 23
FGFR11-10, 14,17
FGFR22, 8-10,13, 16-17
FGFR32-4, 8-10, 16-18
MET2-6, 13-17, 21
NRG11, 1-8
NTRK12, 7-13
NTRK37, 12-18
RAF12, 8-10
RET2-4, 7-13
Turnaround time3 to 5 days
Reproducibility100% (same input replicates), 91.67% (including replicates with different input


Actionable Results

Reduce ambiguity by targeting only actionable mutations.

Rapid Turnaround Time

Make clinical decisions faster, with accurate reporting in just seven days.

Comprehensive Reports

Review detailed interpretations, current treatment options, and available clinical trials.


Reduce the financial burden on healthcare providers and patients with an affordable, reimbursable test.

Conserve Biopsy Tissue

Find It’s single sample panel tests for all hotspots simultaneously, reducing the amount of biopsy tissue required.


All Canexia Health assays were developed under full accreditation of the CAP and CLIA.

View Other Solutions

Follow It®

A minimally invasive option for biopsy, Follow It can also be used to monitor cancer progression or investigate treatment resistance.

Learn About Follow It

Canexia Informatics Platform

Each comprehensive report includes detailed results as well as therapeutic recommendations and expertly curated clinical trials. Our insights can help you make more informed treatment decisions.

Learn About Our Reports

Your Information In Your Control

Perform world-leading mutation testing for cancer patients, right from your laboratory: Canexia Health’s proprietary bioinformatics and reporting platform covers everything from mutation identification to auto-generated clinical reports.

Learn More


Do More For Your Patients

Canexia Health’s expert and cost-effective assays, informatics, and support mean rapid assay results and actionable next steps. Learn how partnering with Canexia can help you make faster treatment decisions.

Get Started Today